Xynomic Closed a Short Form Merger for "Going Private" Transaction
June 17, 2021 08:30 ET
|
Xynomic Pharmaceuticals Holdings, Inc.
NEW YORK, New York and SHANGHAI, June 17, 2021 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, OTC: XYNO), a clinical stage US-China oncology drug development company,...
Xynomic Pharma Receives Fast-Track Designation from the US FDA for Abexinostat as 4L Therapy Treating Follicular Lymphoma
September 23, 2019 06:00 ET
|
Xynomic Pharmaceuticals Holdings, Inc.
SHANGHAI, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, today announced that...
Xynomic Pharma Doses First Chinese Patient in Pivotal Phase 3 Kidney Cancer Trial and Hires Medical Monitor
September 13, 2019 15:58 ET
|
Xynomic Pharmaceuticals Holdings, Inc.
SHANGHAI, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, today announced the...
Xynomic Pharma Reports Encouraging Interim Data from Phase 1b Study of Abexinostat Combined with Keytruda® in Multiple Solid Tumors
August 30, 2019 08:41 ET
|
Xynomic Pharmaceuticals Holdings, Inc.
RALEIGH, N.C. and SHANGHAI, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company,...
Xynomic Research Institute Has Successfully Designed a Series of Potent RET Kinase Inhibitors
August 16, 2019 16:30 ET
|
Xynomic Pharmaceuticals Holdings, Inc.
RALEIGH, N.C. and SHANGHAI, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company,...
Xynomic Pharma Receives Important Accreditation from Independent Ethics Committees of Leading Chinese Cancer Hospitals
August 07, 2019 16:00 ET
|
Xynomic Pharmaceuticals Holdings, Inc.
RALEIGH, N.C. and SHANGHAI, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company,...
Xynomic Filed Fast-Track Designation Application for Follicular Lymphoma Treatment with the U.S. FDA
August 01, 2019 07:00 ET
|
Xynomic Pharmaceuticals Holdings, Inc.
RALEIGH, N.C. and SHANGHAI, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage U.S.-China oncology drug development company,...
Xynomic Received China Approval to Start 2 Pivotal Lymphoma Clinical Trials
July 30, 2019 07:00 ET
|
Xynomic Pharmaceuticals Holdings, Inc.
RALEIGH, N.C. and SHANGHAI, July 30, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company,...
Xynomic Pharma Will Present at 3rd World-China Immunotherapy & Gene Therapy Congress
July 26, 2019 12:29 ET
|
Xynomic Pharmaceuticals Holdings, Inc.
RALEIGH, N.C. and SHANGHAI, July 26, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage U.S.-China oncology drug development company,...
Xynomic Completes Pre-IND Meeting with US FDA for XP-102, a Novel Pan-RAF Inhibitor against Colorectal Cancer and Lung Cancer
June 12, 2019 10:00 ET
|
Xynomic Pharmaceuticals Holdings, Inc.
RALEIGH, N.C. and SHANGHAI, June 12, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, Nasdaq: XYN), a clinical stage US-China oncology drug development company, announced...